Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Fortrea Holdings Inc. - Common Stock
(NQ:
FTRE
)
4.440
-0.310 (-6.53%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 16, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Fortrea Holdings Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Beyond The Numbers: 6 Analysts Discuss Fortrea Holdings Stock
May 13, 2025
Via
Benzinga
Securities Fraud Investigation Into Fortrea Holdings Inc. (FTRE) Continues – Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
May 12, 2025
From
Glancy Prongay & Murray LLP
Via
Business Wire
Fortrea Holdings Inc. (FTRE) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
May 12, 2025
From
Law Offices of Howard G. Smith
Via
Business Wire
Earnings Scheduled For May 12, 2025
May 12, 2025
Via
Benzinga
Securities Fraud Investigation Into Fortrea Holdings Inc. (FTRE) Continues – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
May 12, 2025
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Why Fortrea (FTRE) Stock Is Falling Today
May 12, 2025
Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) fell 14.3% in the afternoon session after the company reported first quarter 2025 earnings as the news of the CEO stepping down...
Via
StockStory
Fortrea’s (NASDAQ:FTRE) Q1: Strong Sales, Full-Year Outlook Slightly Exceeds Expectations
May 12, 2025
Clinical research company Fortrea Holdings (NASDAQ:FTRE) beat Wall Street’s revenue expectations in Q1 CY2025, but sales fell by 1.6% year on year to $651.3 million. The company’s full-year revenue...
Via
StockStory
Fortrea Reports First Quarter 2025 Results
May 12, 2025
From
Fortrea Holdings Inc
Via
GlobeNewswire
Fortrea Announces CEO Stepping Down
May 12, 2025
Peter M. Neupert, Fortrea’s Lead Independent Director, will serve as Interim CEO as Thomas Pike steps down
From
Fortrea Holdings Inc
Via
GlobeNewswire
Earnings To Watch: Fortrea (FTRE) Reports Q1 Results Tomorrow
May 11, 2025
Clinical research company Fortrea Holdings (NASDAQ:FTRE) will be reporting results tomorrow before market open. Here’s what to expect.
Via
StockStory
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
3 Volatile Stocks Skating on Thin Ice
May 09, 2025
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced...
Via
StockStory
Fortrea Named a Leader in Everest Group’s Pharmacovigilance Operations PEAK Matrix® Assessment 2025
May 01, 2025
Recognized in both pre-and post-approval pharmacovigilance operations
From
Fortrea Holdings Inc
Via
GlobeNewswire
3 Small-Cap Stocks Skating on Thin Ice
May 01, 2025
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside...
Via
StockStory
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE
April 25, 2025
From
Pomerantz LLP
Via
GlobeNewswire
1 Cash-Producing Stock That Stand Out and 2 to Be Wary Of
April 22, 2025
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...
Via
StockStory
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE
April 21, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE
April 17, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Fortrea Announces Date for First Quarter 2025 Financial Results and Conference Call
April 15, 2025
From
Fortrea Holdings Inc
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE
April 12, 2025
From
Pomerantz LLP
Via
GlobeNewswire
1 Oversold Stock Primed to Rebound and 2 to Approach with Caution
April 10, 2025
Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.
Via
StockStory
Demystifying Fortrea Holdings: Insights From 4 Analyst Reviews
April 09, 2025
Via
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Fortrea Holdings Inc. - FTRE
April 07, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE
April 03, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE
March 30, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE
March 26, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks
March 26, 2025
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how IQVIA (NYSE:IQV) and the rest...
Via
StockStory
Bragar Eagel & Squire, P.C. Is Investigating Fortrea and Ibotta and Encourages Investors to Contact the Firm
March 25, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
Unpacking Q4 Earnings: West Pharmaceutical Services (NYSE:WST) In The Context Of Other Drug Development Inputs & Services Stocks
March 25, 2025
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at West Pharmaceutical Services (NYSE:WST) and its peers.
Via
StockStory
Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers
March 21, 2025
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Medpace (NASDAQ:MEDP) and its peers.
Via
StockStory
Securities Fraud Investigation Into Fortrea Holdings Inc. (FTRE) Continues – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
March 20, 2025
From
Glancy Prongay & Murray LLP
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.